FACULTY
Patricia Kaazan, MD, FRACP
Flinders Medical Centre, IBDSA
The University of Adelaide
Adelaide, South Australia
Stephanie Gold, MD
Assistant Professor of Medicine
Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine, Mount Sinai
New York, New York
PROGRAM OVERVIEW
This program has been designed to enhance learners’ understanding of the complex pathophysiologic relationship linking gut microbiota and inflammation to obesity and inflammatory bowel disease (IBD). Participants will gain insight on the clinical application of findings from pharmacologic trials to optimize the management of patients with obesity and IBD via real word case studies. The program emphasizes a multidisciplinary approach to care, highlighting the identification of negative outcomes linked to obesity and IBD, and promotes the integration of comorbidity awareness into comprehensive patient care plan.
TARGET AUDIENCE
The proposed education will be designed to meet the needs of specialists including gastroenterologists and gastroenterology nurse practitioners and physician assistants treating patients with IBD and obesity on a global level.
LEARNING OBJECTIVES
- Describe the intricate pathophysiologic interplay between gut inflammation and obesity
- Apply pharmacologic trials findings for both obesity and IBD to optimize care of each concomitantly
- Develop a multidisciplinary team approach to the management of patients with obesity and IBD
- Incorporate an understanding of the comorbidities and negative healthcare outcomes associated with obesity in the IBD patient care plan
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Patricia Kaazan, MD | She received speaker fees from AbbVie, Pfizer, Johnson & Johnson, and Falk Pharma. Additionally, she has delivered educational presentations in collaboration with Research Review Australia. |
| Stephanie Gold, MD | She receives support through a Crohn’s and Colitis Clinical Research Investigator-Initiated Award, serves as the 2023–2024 Nestlé Nutrition Fellow, and holds a position on the Medical Advisory Board for Nutritional Therapy in Inflammatory Bowel Disease (IBD). |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Shilpa Lalchandani, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, M.S. For, Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 05, 2025
EXPIRATION DATE: June 05, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Patricia Kaazan, MD, FRACP
Flinders Medical Centre, IBDSA
The University of Adelaide
Adelaide, South Australia
PROGRAM OVERVIEW
In the opening episode of our two-part podcast series we explore the ever-evolving understanding of the intricate interplay between obesity and gut inflammation. This session unravels the complex pathophysiologic mechanisms linking adipose tissue, immune dysregulation, gut microbiota, and inflammatory bowel disease (IBD). Listeners will uncover how obesity fuels systemic inflammation while profoundly influencing IBD’s expression, severity, and response to treatment. By the episode’s close, healthcare professionals will gain a clearer grasp of the pathways connecting these two disorders, enabling them to deliver more precise and comprehensive patient care with confidence and insight.
TARGET AUDIENCE
The proposed education will be designed to meet the needs of specialists including gastroenterologists and gastroenterology nurse practitioners and physician assistants treating patients with IBD and obesity on a global level.
LEARNING OBJECTIVES
Upon completion of this program, attendees should be able to:
- Describe the intricate pathophysiologic interplay between gut inflammation and obesity
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Patricia Kaazan, MD | She received speaker fees from AbbVie, Pfizer, Johnson & Johnson, and Falk Pharma. Additionally, she has delivered educational presentations in collaboration with Research Review Australia. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Shilpa Lalchandani, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, M.S. For, Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: May 30, 2025
EXPIRATION DATE: May 30, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Stephanie Gold, MD
Assistant Professor of Medicine
Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine, Mount Sinai
New York, New York
PROGRAM OVERVIEW
In the second installment of our two-part podcast series, we explore the latest clinical trial data in obesity and inflammatory bowel disease (IBD), focusing on how to weave these findings into seamless, evidence-based care for patients grappling with both conditions. Our discussion spotlights the efficacy and safety data on GLP-1 receptor agonists, biologics, and small molecules weighing their potential to transform treatment of these overlapping disorders while addressing inherent risks. By the episode’s close, healthcare professionals will emerge equipped to critically apply cutting-edge evidence, tailor personalized care, boost patient outcomes, and master the complexities of managing patients with obesity and IBD in tandem.
TARGET AUDIENCE
The proposed education will be designed to meet the needs of specialists including gastroenterologists and gastroenterology nurse practitioners and physician assistants treating patients with IBD and obesity on a global level.
LEARNING OBJECTIVES
Upon completion of this program, attendees should be able to:
- Apply pharmacologic trials findings for both obesity and IBD to optimize care of each concomitantly
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Stephanie Gold, MD | She receives support through a Crohn’s and Colitis Clinical Research Investigator-Initiated Award, serves as the 2023–2024 Nestlé Nutrition Fellow, and holds a position on the Medical Advisory Board for Nutritional Therapy in Inflammatory Bowel Disease (IBD). |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Shilpa Lalchandani, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, M.S. For, Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: May 30, 2025
EXPIRATION DATE: May 30, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
